Effect of anisoon and sumaq in patients of vulvovaginal candidiasis

Therapeutic evaluation of hamul of anisoon (pimpinella anisum) and sumaq (rhus coriaria) in vulvovaginal Candidiasis A randomized standard controlled clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/102943

Enrollment

Registered

2026-02-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B373- Candidiasis of vulva and vagina

Interventions

Intervention1: Hamul Of Anisoon (Pimpinella anisum) And Sumaq (Rhus coriaria): Hamul Of Anisoon And Sumaq Each Of 2gm Will be Given Per Vaginally At Bed Time Daily For 21 days Control Intervention1: C

Eligibility

Inclusion criteria

Inclusion criteria: Married women between 18 to 49 years of age Complaint of vaginal pruritus dysuria dyspareunia and thick curdy vaginal discharge Positive KOH mount Negative Whiff Vaginal pH less or equal 4

Exclusion criteria

Exclusion criteria: Unmarried pregnant and lactating women Systemic illness and Immunocompromised patients Menopausal women History of anti-fungal antibiotic or corticosteroid therapies within past 2 weeks Patients with diabetes mellitus History of malignancy Women with STDs genital prolapse Hypersensitivity or allergy to clotrimazole

Design outcomes

Primary

Measure	Time frame
Complete cure and Reduction in the subjective symptoms along with negative KOH mount for hyphaeTimepoint: 21 days	—

Secondary

Measure	Time frame
Adverse effects Non recurrence of symptoms within two months after completion of the therapy Timepoint: 21 days	—

Countries

India

Contacts

Public ContactDr Km Fatima

State Takmeeluttib College and Hospital

dr_maniramsingh@rediffmail.com8423307654

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026